A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy

被引:21
作者
Campbell, M
Sonkodi, S
Soucek, M
Wiecek, A
机构
[1] Southbank Surg, Glasgow, Lanark, Scotland
[2] Albert Szent Gyorgyi Med Univ, Belgyogyaszati Klin, Szeged, Hungary
[3] Fak Nemocnice SV Anny, Interni Klin 1, Brno, Czech Republic
[4] Slaska Akad Medyczna, Klin Nefrol, Katowice, Poland
关键词
hypertension; candesartan cilexetil; hydrochlorothiazide; combination treatment;
D O I
10.1081/CEH-100102672
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this double-blind, placebo-controlled, randomised, parallel-group study, a combination tablet of candesartan cilexetil/hydrochlorothiazide (HCTZ), 16/12.5 mg once daily, reduced sitting diastolic blood pressure (DBP) significantly more (p = 0.037) than candesartan cilexetil/placebo, 16 mg once daily, in patients with mild to moderate primary hypertension (n = 328) who had not reached target blood pressure with candesartan cilexetil, 16 mg once daily. Ar the end of the 8-week double-blind treatment period, the adjusted mean reductions in sitting DBP, 24 h post dose, were 7.5 mm Hg in the candesartan cilexetil/HCTZ treatment group and 5.5 mm Hg in the candesartan cilexetil/placebo treatment group, corresponding to an adjusted mean difference between treatments of 2.0 mm Hg in favour of candesartan cilexetil/HCTZ (95% CI 0.1-3.8 mm Hg, p = 0.037). The adjusted mean reductions in sitting systolic blood pressure, 24 h post dose, were 12.0 mm Hg and 7.5 mm Hg, respectively, corresponding to an adjusted mean difference between treatments of 4.5 mm Hg (95% CI 1.1-8.0, p = 0.01). Consistent with the placebo-like tolerability of candesartan cilexetil reported in other studies, both treatments were very well tolerated, with a similar pattern and low frequency of adverse events in both treatment groups.
引用
收藏
页码:345 / 355
页数:11
相关论文
共 26 条
  • [1] [Anonymous], MANUAL HYPERTENSION
  • [2] PREVALENCE OF HYPERTENSION IN THE US ADULT-POPULATION - RESULTS FROM THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY, 1988-1991
    BURT, VL
    WHELTON, P
    ROCCELLA, EJ
    BROWN, C
    CUTLER, JA
    HIGGINS, M
    HORAN, MJ
    LABARTHE, D
    [J]. HYPERTENSION, 1995, 25 (03) : 305 - 313
  • [3] Chalmers J, 1999, J HYPERTENS, V17, P151
  • [4] Blood pressure screening, management and control in England: results from the health survey for England 1994
    Colhoun, HM
    Dong, W
    Poulter, NR
    [J]. JOURNAL OF HYPERTENSION, 1998, 16 (06) : 747 - 752
  • [5] Elmfeldt D, 1997, J HUM HYPERTENS, V11, pS49
  • [6] HEMODYNAMIC AND HUMORAL EFFECTS OF THE ANGIOTENSIN-II ANTAGONIST LOSARTAN IN ESSENTIAL-HYPERTENSION
    GROSSMAN, E
    PELEG, E
    CARROLL, J
    SHAMISS, A
    ROSENTHAL, T
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1994, 7 (12) : 1041 - 1044
  • [7] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial
    Hansson, L
    Zanchetti, A
    Carruthers, SG
    Dahlöf, B
    Elmfeldt, D
    Julius, S
    Ménard, J
    Rahn, KH
    Wedel, H
    Westerling, S
    [J]. LANCET, 1998, 351 (9118) : 1755 - 1762
  • [8] Heuer HJ, 1997, J HUM HYPERTENS, V11, pS55
  • [9] IACONO P, 1992, INT J CLIN PHARM RES, V12, P53
  • [10] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .1. PROLONGED DIFFERENCES IN BLOOD-PRESSURE - PROSPECTIVE OBSERVATIONAL STUDIES CORRECTED FOR THE REGRESSION DILUTION BIAS
    MACMAHON, S
    PETO, R
    CUTLER, J
    COLLINS, R
    SORLIE, P
    NEATON, J
    ABBOTT, R
    GODWIN, J
    DYER, A
    STAMLER, J
    [J]. LANCET, 1990, 335 (8692) : 765 - 774